Table 1 Summary of the baseline characteristics of the participants included in the randomized controlled trials
From: The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
GLP-1 RA | Design | Sample size | Duration (weeks) | Female (%) | Mean age (years) | Mean HbA1c (%) | Mean body mass index (kg/m2) | Mean body weight (kg) | |
|---|---|---|---|---|---|---|---|---|---|
Arslanian 2022 | Dulaglutide | Randomized, parallel-group, placebo-controlled, double-blind, multicenter, phase 3 superiority clinical trial. | 154 | 26 | 71 | 14.5 ± 2.0 | 8.1 ± 1.3 | 34.1 ± 8.8 | 90.5 ± 26.5 |
Tamborlane 2022 | Exenatide | Randomized, parallel-group, placebo-controlled, double-blind, multicenter, phase 3 clinical trial. | 83 | 24 | 58.5 | 15 ± 1.8 | 8.2 ± 1.3 | 36.36 ± 8.57 | 100.6 ± 28.1 |
Tamborlane 2019 | Liraglutide | Randomized, parallel-group, placebo-controlled, double-blind, multicenter, phase 3 clinical trial. | 134 | 26 | 61.9 | 14.6 ± 1.7 | 7.78 ± 1.34 | 33.90 ± 9.25 | 91.5 ± 26.8 |
Barrientos-Pérez 2022 | Lixisenatide | Randomized, parallel-group, placebo-controlled, double-blind, multicenter, phase 1 clinical trial. | 23 | 6 | 69.57 | 15.56 | 8.16 | 34.11 | 92.76 |
Klein 2014 | Liraglutide | Randomized, parallel-group, placebo-controlled, double-blind, multicenter clinical trial. | 21 | 5 | 66.67 | 14.8 ± 2.2 | 8.1 ± 1.2 | 40 | 113.2 ± 35.6 |